可孚医疗科技股份有限公司2022年年度报告全文 可孚医疗科技股份有限公司 2022 年年度报告 2023-021 ...

Financial Performance - The company's revenue for Q1 2023 reached ¥855,367,818.78, representing a 42.38% increase compared to ¥600,753,831.09 in the same period last year[5] - Net profit attributable to shareholders was ¥134,514,033.42, a significant increase of 167.93% from ¥50,204,732.44 year-on-year[5] - The basic earnings per share rose to ¥0.65, up 170.83% from ¥0.31 in the previous year[5] - Operating profit for Q1 2023 was ¥157,563,269.47, compared to ¥59,566,256.94 in Q1 2022, reflecting a growth of 164.6%[23] - Net profit for Q1 2023 amounted to ¥155,540,561.37, a substantial increase from ¥58,840,441.70 in the previous year[23] - The net profit for Q1 2023 was CNY 133,373,483.95, a significant increase of 153% compared to CNY 52,632,513.24 in the same period last year[25] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.65, up from CNY 0.24 in Q1 2022, representing a 171% increase[25] Cash Flow and Liquidity - Operating cash flow improved to ¥154,022,832.30, a turnaround from a negative cash flow of ¥317,768,933.80 in the same period last year, marking a 148.47% increase[5] - The net cash flow from operating activities was ¥154,022,832.30, a significant improvement from the previous period's negative cash flow of -¥317,768,933.80, representing a change of -148.47% due to reduced payments to suppliers and increased sales collections[14] - Cash flow from operating activities generated a net cash inflow of CNY 154,022,832.30, compared to a net outflow of CNY 317,768,933.80 in the previous year[28] - Cash and cash equivalents at the end of the period were ¥1,417,777,818.28, slightly down from ¥1,449,959,044.04 at the beginning of the year[22] - Cash and cash equivalents at the end of Q1 2023 were CNY 1,320,497,604.99, down from CNY 1,730,252,830.26 at the end of Q1 2022[29] Expenses and Costs - Total operating costs for Q1 2023 were ¥676,950,984.19, up 26.3% from ¥536,028,236.07 in Q1 2022[23] - Research and development expenses increased by 39.82% to ¥29,501,924.78, reflecting higher personnel costs and material expenses[13] - The company reported a significant increase in research and development expenses, which rose to ¥29,501,924.78 from ¥21,100,488.96, marking an increase of 39.6%[23] - The company reported a 57.12% increase in sales expenses, totaling ¥195,901,260.69, due to higher service fees and marketing costs[13] Assets and Liabilities - The company's total assets at the end of Q1 2023 were ¥6,360,300,564.21, a slight decrease of 0.79% from ¥6,410,837,630.17 at the end of the previous year[5] - Total assets decreased to ¥6,360,300,564.21 from ¥6,410,837,630.17, a decline of 0.8%[22] - Total liabilities decreased to ¥1,326,522,271.57 from ¥1,377,934,885.05, a reduction of 3.7%[22] - The company experienced a 253.00% increase in long-term borrowings, reaching ¥106,000,000.00, primarily due to new loans taken during the period[11] Shareholder Information and Repurchase Plans - As of the end of the reporting period, the total number of ordinary shareholders was 23,304, with no preferred shareholders[16] - The largest shareholder, Changsha Medical Investment Co., Ltd., holds 40.81% of the shares, amounting to 85,079,923 shares, with 23,010,000 shares pledged[16] - The company plans to repurchase shares using self-owned funds, with a total repurchase amount not less than ¥100 million and not exceeding ¥200 million, at a price not exceeding ¥60.00 per share[18] - As of March 31, 2023, the company had repurchased a total of 3,680,769 shares, representing 1.77% of the total share capital, with a total transaction amount of ¥136,317,242.94[19] - The highest repurchase price was ¥37.94 per share, while the lowest was ¥36.00 per share[19] - The company is focused on implementing an employee stock ownership plan or equity incentive through the repurchased shares[18] Strategic Focus - The report indicates a strategic focus on improving cash flow management and shareholder value through share repurchases and operational efficiency[14] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[23] Other Financial Metrics - The company's weighted average return on equity improved to 2.69%, an increase of 1.68 percentage points from the previous year[5] - The impact of exchange rate fluctuations on cash and cash equivalents was -¥85,583.07, which is a 634.04% increase from -¥11,659.26 in the previous period, attributed to increased exchange rate volatility[14] - The company reported a total cash outflow from financing activities of CNY 413,806,436.72, compared to CNY 240,826,576.86 in the previous year[29] - The net cash flow from investing activities was negative CNY 115,099,925.82, an improvement from negative CNY 163,099,190.61 in the same period last year[28] - The company received CNY 324,848,762.14 in cash from borrowings during Q1 2023, compared to CNY 498,163,187.40 in the previous year[28] - The report for Q1 2023 was not audited[30]

编号：2021-006 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|----------------------------------------------------------------------|------------------------------------------------------------------------| | 投资者关系活动类别 | □特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n☑其他 电话会议 | □分析师会议 \n □业绩说明会 \n □路演活动 \n | | 参与单位名称及人员 | | 富国基金孙笑悦、蒲世林；安信基金池陈森；乘安资管王镜程；东证资管周琰； | | 姓名 | | 中海基金梁静静；东方基金蔡尚军；东吴自营于彦秋；工银瑞信基金李乾宁； | | | | 广发基金王琪；大成基金邹建、杨挺、陈泉龙、戴军；光大永明资产王申璐； | | | | 国寿安保基金祁善斌；泓澄投资樊翔宇；弘毅远方基金 ...

Group 1: Company Overview and Development Plans - The company has been deeply engaged in the medical device industry for over ten years, with leading products such as hearing aids and infrared thermometers [1] - Key research projects include continuous glucose monitoring and advanced ECG monitoring, among others [1] - In 2020, the revenue from self-produced products accounted for 51%, with plans to increase this ratio through new production bases [1] Group 2: Acquisition and Market Position - The acquisition of the "Beibeijia" brand aims to leverage its strong market presence in posture correction products, which has been a leading brand for 20 years [2] - The brand will be enhanced through collaborations with universities and medical institutions to meet medical correction standards [2] - The company plans to optimize marketing strategies and reduce operational costs through its strong e-commerce capabilities [2] Group 3: Impact of COVID-19 - The pandemic increased health awareness and demand for health-related products, leading to a surge in sales of thermometers and masks [2] - In 2021, as the pandemic situation improved, non-pandemic product revenues rebounded, with total revenue reaching 1.698 billion yuan and net profit of 304 million yuan [2] Group 4: Hearing Loss and Service Model - Hearing loss is categorized into conductive, sensorineural, and mixed types, with recommendations for hearing aids for patients unable to restore normal hearing [2] - The company has established over 300 hearing aid fitting centers, employing a direct management model to ensure service quality and brand recognition [3][4]

编号：2021-003 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：2021-005 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | ☑ 特定对象调研 \n□媒体采访 \n□新闻发布会 \n□现场参观 \n☑其他 电话会议 | □分析师会议 \n □业绩说明会 \n □路演活动 \n | | 参与单位名称及人员 | | 广发证券罗佳荣、漆经纬、朱新彦；长城基金谭小兵、陈蔚丰 ...

编号：2021-001 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动类别 | 特定对象调研 | □分析师会议 | | | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及人员 姓名 | 大成基金 | 邹建、齐炜中、杨挺、吕乐艺、陈泉龙 | | 时间 | 2021-11-09 | | | 地点 | 健耳听力门店、公司会议室 | | | 上市公司接待人员姓 名 | 董事长/总裁 ...

编号：2021-008 证券代码：301087 证券简称：可孚医疗 可孚医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |-----------------------|----------------------------------------|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | 投资者关系活动类别 | 特定对象调研 | □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | | □新闻发布会 | □路演活 ...